FindTrial
Sign In

Young TIL

BIOLOGICAL7 trials

Sponsors

National Cancer Institute (NCI)

Conditions

AdenocarcinomaAdenosquamous CarcinomaAdvanced NSCLCAdvanced Non-Small Cell Lung CancerAnal CancerCervical CancerMelanomaMetastatic Breast Carcinoma

Phase 1

Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
TerminatedNCT01585415
National Cancer Institute (NCI)Melanoma, Metastatic Cancer
Start: 2012-04-09End: 2016-07-21Updated: 2019-11-21

Phase 2

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RecruitingNCT01174121
National Cancer Institute (NCI)Metastatic Breast Carcinoma, Metastatic Colorectal Cancer, Metastatic Endocrine Tumors/ Neuroendocrine Tumors +2
Start: 2010-08-26End: 2029-12-27Target: 332Updated: 2026-09-16
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
CompletedNCT01319565
National Cancer Institute (NCI)Metastatic Melanoma, Skin Cancer
Start: 2011-03-24End: 2024-09-10Updated: 2025-12-19
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
CompletedNCT01585428
National Cancer Institute (NCI)Anal Cancer, Cervical Cancer, Oropharyngeal Cancer +2
Start: 2012-04-13End: 2016-08-01Updated: 2018-03-07
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
CompletedNCT01993719
National Cancer Institute (NCI)Metastatic Melanoma
Start: 2013-12-12End: 2022-07-06Updated: 2023-01-18
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RecruitingNCT02133196
National Cancer Institute (NCI)Adenocarcinoma, Adenosquamous Carcinoma, Advanced Non-Small Cell Lung Cancer +2
Start: 2014-10-23End: 2027-10-23Target: 85Updated: 2026-08-31
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RecruitingNCT02621021
National Cancer Institute (NCI)Melanoma
Start: 2015-12-04End: 2029-06-16Target: 53Updated: 2026-08-20

Related Papers

Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial.
2025-04-0125 citations
Recent Advancements in Cell-Based Therapies in Melanoma.
2024-09-124 citations
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
Journal for ImmunoTherapy of Cancer2024-05-0124 citations
1216 Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
Regular and Young Investigator Award Abstracts2023-10-31
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes
Journal of Clinical Oncology2022-02-01163 citations
184 Adoptive T cell therapies targeting common p53 neoantigens in human solid cancers
Regular and Young Investigator Award Abstracts2021-11-01
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types
Journal for ImmunoTherapy of Cancer2021-10-0161 citations
Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells.
Journal of Clinical Oncology2018-05-209 citations
A randomized, prospective evaluation comparing intensity of lymphodepletion prior to adoptive transfer of tumor infiltrating lymphocytes for patients with metastatic melanoma.
Journal of Clinical Oncology2016-05-206 citations
Abstract OT1-01-03: Adoptive cell transfer (ACT) using tumor infiltrating lymphocytes to target neoantigens in patients with metastatic breast cancer
Cancer Research2016-02-151 citations
HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.
Journal of Clinical Oncology2014-06-2023 citations
HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.
Journal of Clinical Oncology2014-05-208 citations